VaxGen, Inc. (Public, OTC: VXGN)’s peer-reviewed data from the company's Phase I clinical trial of its candidate anthrax vaccine rPA102 were published in the journal Vaccine(1).
The data which demonstrated a clear relationship between the rPA102 dose administration and the subsequent immune response were reported in the paper entitled "Immunogenicity and Tolerance of Ascending Doses of a Recombinant Protective Antigen (rPA102) Anthrax Vaccine: A Randomized, Double-blinded, Controlled, Multicenter Trial.”
"We need a better vaccine to help protect people from anthrax infection, whether the vaccine is given before or soon after exposure to anthrax spores," said Geoffrey J. Gorse, M.D., Professor of Internal Medicine, Saint Louis School of Medicine and lead author of the paper.
"In this study we were able to demonstrate that the investigational anthrax vaccine produced an immune response that justifies further testing in larger studies. Data from this study will be used to help design strategies for testing this vaccine in the future."
rPA102 (cannot cause anthrax infection) is a recombinant Protective Antigen (PA) protein vaccine that was initially developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
VaxGen’s vaccine candidate contains the protein (Protective Antigen,) produced using recombinant technology from a strain of B. anthracis bacteria that is genetically modified to prevent the production of spores, toxins or virulence factors.
The above study was conducted by Geoffrey J. Gorse, M.D., at the Saint Louis University School of Medicine, along with colleagues at Baylor College of Medicine, Emory University School of Medicine, Johns Hopkins University and VaxGen.
Source: VaxGen, Inc. (a pdf file)
(1) Gorse, GJ, et al. 2006. Immunogenicity and Tolerance of Ascending Doses of a Recombinant Protective Antigen (rPA102) Anthrax Vaccine: a Randomized, Double-Blinded, Controlled, Multicenter Trial. Vaccine 24(33-34):5950-5959.
.jpg)
Comment Preview